DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average daily volume of 113,800 shares, the short-interest ratio is currently 2.0 days.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $40,000. Balyasny Asset Management L.P. purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at $79,000. Y Intercept Hong Kong Ltd bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $81,000. Raymond James Financial Inc. bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $83,000. Finally, Bank of Montreal Can purchased a new position in shares of DiaMedica Therapeutics in the fourth quarter worth $84,000. 10.12% of the stock is owned by hedge funds and other institutional investors.
DiaMedica Therapeutics Stock Performance
Shares of DMAC traded down $0.30 during trading hours on Monday, hitting $5.47. The company had a trading volume of 97,340 shares, compared to its average volume of 68,897. The stock has a market capitalization of $233.90 million, a price-to-earnings ratio of -9.77 and a beta of 1.52. The firm has a fifty day moving average price of $5.93 and a 200-day moving average price of $5.02. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.
Check Out Our Latest Report on DMAC
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Recommended Stories
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
